Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CHOP and Intrathecal Methotrexate in Primary Breast DLBCL
NCT01448096Phase 2Completed
- Sponsor
- Jeonbuk National University Hospital
- Start
- Aug 2011
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab and methotrexate in diffuse large B-cell lymphoma (DLBCL), sponsored by Jeonbuk National University Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Aug 2011; status: completed.
02
Drugs
rituximabmethotrexate
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01448096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01448096.